Company profile
Ticker
OMER
Exchange
Website
CEO
Dr. Gregory A. Demopulos M.D.
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
SEC CIK
Corporate docs
IRS number
911663741
OMER stock data
Analyst ratings and price targets
Latest filings (excl ownership)
8-K
Omeros Announces Update on Statistical Analysis of Narsoplimab Pivotal Trial Primary Endpoint
16 Jan 25
8-K
Other Events
19 Dec 24
10-Q
2024 Q3
Quarterly report
13 Nov 24
8-K
Omeros Corporation Reports Third Quarter 2024 Financial Results
13 Nov 24
10-Q
2024 Q2
Quarterly report
7 Aug 24
8-K
Omeros Corporation Reports Second Quarter 2024 Financial Results
7 Aug 24
8-K
Departure of Directors or Certain Officers
12 Jun 24
8-K
Entry into a Material Definitive Agreement
3 Jun 24
10-Q
2024 Q1
Quarterly report
15 May 24
8-K
Omeros Corporation Reports First Quarter 2024 Financial Results
15 May 24
Transcripts
OMER
Earnings call transcript
2024 Q3
13 Nov 24
OMER
Earnings call transcript
2024 Q2
7 Aug 24
OMER
Earnings call transcript
2024 Q1
15 May 24
OMER
Earnings call transcript
2023 Q4
1 Apr 24
OMER
Earnings call transcript
2023 Q3
9 Nov 23
OMER
Earnings call transcript
2023 Q2
9 Aug 23
OMER
Earnings call transcript
2023 Q1
9 May 23
OMER
Earnings call transcript
2022 Q4
13 Mar 23
OMER
Earnings call transcript
2022 Q3
10 Nov 22
OMER
Earnings call transcript
2022 Q2
10 Aug 22
Latest ownership filings
Financial summary
Quarter (USD) | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | |||
---|---|---|---|---|---|---|
Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q | |
Cash on hand (at last report) | 1.52 mm | 1.52 mm | 1.52 mm | 1.52 mm | 1.52 mm | 1.52 mm |
Cash burn (monthly) | 199.67 k | 2.43 mm | 11.80 mm | 14.45 mm | 10.69 mm | 12.89 mm |
Cash used (since last report) | 932.65 k | 11.33 mm | 55.13 mm | 67.48 mm | 49.91 mm | 60.20 mm |
Cash remaining | 588.35 k | -9.81 mm | -53.61 mm | -65.96 mm | -48.39 mm | -58.68 mm |
Runway (months of cash) | 2.9 | -4.0 | -4.5 | -4.6 | -4.5 | -4.6 |
Institutional ownership, Q3 2024
46.3% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 109 |
Opened positions | 16 |
Closed positions | 12 |
Increased positions | 26 |
Reduced positions | 34 |
13F shares | Current |
---|---|
Total value | 80.08 bn |
Total shares | 26.81 mm |
Total puts | 408.36 k |
Total calls | 227.50 k |
Total put/call ratio | 1.8 |
Largest owners | Shares | Value |
---|---|---|
Ingalls & Snyder | 4.54 mm | $18.02 mm |
BlackRock | 4.23 mm | $16.79 bn |
Vanguard | 3.26 mm | $12.94 bn |
SF Stifel Financial | 1.90 mm | $7.56 bn |
D. E. Shaw & Co | 1.79 mm | $25.15 mm |
D. E. Shaw & Co. | 1.61 mm | $6.37 bn |
Geode Capital Management | 1.34 mm | $5.32 bn |
STT State Street | 1.23 mm | $4.87 bn |
CI Private Wealth | 786.45 k | $3.12 bn |
BMO Bank of Montreal | 563.10 k | $2.21 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
6 Jun 24 | Demopulos Peter A MD | Stock Option Common Stock | Grant | Acquire A | No | No | 3.91 | 15,000 | 58.65 k | 15,000 |
6 Jun 24 | Hanish Arnold C | Stock Option Common Stock | Grant | Acquire A | No | No | 3.91 | 15,000 | 58.65 k | 15,000 |
6 Jun 24 | Bumol Thomas F. | Stock Option Common Stock | Grant | Acquire A | No | No | 3.91 | 15,000 | 58.65 k | 15,000 |
6 Jun 24 | Hood Leroy E. MD PhD | Stock Option Common Stock | Grant | Acquire A | No | No | 3.91 | 15,000 | 58.65 k | 15,000 |
News
Needham Reiterates Hold on Omerosto Hold
1mo ago
D. Boral Capital Maintains Buy on Omeros, Maintains $36 Price Target
1mo ago
meros Announces Sensitivity Results For Narsoplimab In TA-TMA Patients, Confirming Over 3-Fold Mortality Risk Reduction; Primary Endpoint Met. BLA Resubmission To FDA This Quarter, MAA Submission In Europe By Mid-Year.
1mo ago
This Omeros Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
1mo ago
D. Boral Capital Initiates Coverage On Omeros with Buy Rating, Announces Price Target of $36
1mo ago
Press releases
Omeros Corporation Announces Availability on its Website of Materials Accompanying Narsoplimab Presentations at the 2025 Tandem Meetings
4d ago
Omeros Corporation Announces Upcoming Presentations Detailing Outcomes of Narsoplimab Treatment for TA-TMA Under an Expanded Access Program
1w ago
Omeros Announces Update on Statistical Analysis of Narsoplimab Pivotal Trial Primary Endpoint
1mo ago
Omeros' Narsoplimab Meets its Pivotal Trial Primary Endpoint – Statistical Analysis Shows Survival Superiority Over External Control in Patients with TA-TMA
2mo ago
Omeros Corporation Announces Presentation of Positive Zaltenibart Data at ASH Annual Meeting
2mo ago